$ASMB
Assembly Biosciences Inc

2020 Q1 Form 10-Q Financial Statement

#000156459020023566 Filed on May 08, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q1
Revenue $4.081M $4.767M $3.885M
YoY Change 5.05% 27.63% 8.98%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.730M $10.83M $9.520M
YoY Change -8.3% 22.93% 67.02%
% of Gross Profit
Research & Development $23.05M $22.62M $22.70M
YoY Change 1.52% 6.45% 56.14%
% of Gross Profit
Depreciation & Amortization $115.0K $110.0K $135.0K
YoY Change -14.81% -35.29% -19.64%
% of Gross Profit
Operating Expenses $31.78M $33.45M $32.22M
YoY Change -1.38% 11.29% 59.22%
Operating Profit -$27.69M -$28.34M
YoY Change -2.27% 69.96%
Interest Expense $1.040M $860.0K $1.280M
YoY Change -18.75% -33.85% 204.76%
% of Operating Profit
Other Income/Expense, Net $1.039M $0.00 $1.277M
YoY Change -18.64% 201.89%
Pretax Income -$26.66M -$27.83M -$27.06M
YoY Change -1.49% 11.23% 66.53%
Income Tax $0.00 -$740.0K -$7.000K
% Of Pretax Income
Net Earnings -$26.66M -$27.08M -$27.05M
YoY Change -1.47% 3.53% 66.48%
Net Earnings / Revenue -653.15% -568.16% -696.32%
Basic Earnings Per Share -$0.76 -$1.05
Diluted Earnings Per Share -$0.76 -$976.2K -$1.05
COMMON SHARES
Basic Shares Outstanding 32.62M 25.54M
Diluted Shares Outstanding 35.08B 25.67B

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $249.1M $274.0M $193.5M
YoY Change 28.75% 25.66% 77.2%
Cash & Equivalents $42.33M $46.73M $29.11M
Short-Term Investments $206.8M $227.3M $164.4M
Other Short-Term Assets $4.600M $5.400M $4.300M
YoY Change 6.98% 170.0% 138.89%
Inventory
Prepaid Expenses
Receivables $3.100M $3.374M $2.987M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $256.8M $282.8M $200.8M
YoY Change 27.86% 27.09% 77.39%
LONG-TERM ASSETS
Property, Plant & Equipment $1.780M $1.830M $2.079M
YoY Change -14.38% 228.55% 197.0%
Goodwill $12.64M $12.64M $12.64M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.661M $1.684M $1.661M
YoY Change 0.0% -49.7%
Total Long-Term Assets $56.56M $57.13M $58.44M
YoY Change -3.22% 25.44% 36.54%
TOTAL ASSETS
Total Short-Term Assets $256.8M $282.8M $200.8M
Total Long-Term Assets $56.56M $57.13M $58.44M
Total Assets $313.3M $339.9M $259.2M
YoY Change 20.85% 26.81% 66.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.104M $1.731M $2.400M
YoY Change -12.33% -53.13% 0.0%
Accrued Expenses $4.430M $8.286M $10.14M
YoY Change -56.32% -14.39% 120.46%
Deferred Revenue $6.715M $6.411M
YoY Change 25.71%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $21.15M $24.44M $25.21M
YoY Change -16.1% 32.31% 106.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $37.90M $39.70M $40.40M
YoY Change -6.19% 11.2% 2.8%
Total Long-Term Liabilities $37.90M $39.70M $40.40M
YoY Change -6.19% 2.0% 2.8%
TOTAL LIABILITIES
Total Short-Term Liabilities $21.15M $24.44M $25.21M
Total Long-Term Liabilities $37.90M $39.70M $40.40M
Total Liabilities $61.54M $66.69M $68.85M
YoY Change -10.61% 16.2% 28.44%
SHAREHOLDERS EQUITY
Retained Earnings -$466.1M -$439.4M -$368.8M
YoY Change 26.36% 28.57%
Common Stock $717.9M $712.8M $26.00K
YoY Change 2761169.23% 28.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $251.8M $273.2M $190.4M
YoY Change
Total Liabilities & Shareholders Equity $313.3M $339.9M $259.2M
YoY Change 20.85% 26.81% 66.18%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q1
OPERATING ACTIVITIES
Net Income -$26.66M -$27.08M -$27.05M
YoY Change -1.47% 3.53% 66.48%
Depreciation, Depletion And Amortization $115.0K $110.0K $135.0K
YoY Change -14.81% -35.29% -19.64%
Cash From Operating Activities -$25.22M -$20.53M -$23.94M
YoY Change 5.34% 22.71% 54.45%
INVESTING ACTIVITIES
Capital Expenditures $65.00K -$10.00K $1.488M
YoY Change -95.63% -95.24% 3715.38%
Acquisitions
YoY Change
Other Investing Activities $20.76M -$95.00M $12.92M
YoY Change 60.68% 53.35% -1318.87%
Cash From Investing Activities $20.69M -$95.02M $11.44M
YoY Change 80.96% 52.86% -1139.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00 $100.0K
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 119.0K 137.4M 140.0K
YoY Change -15.0% 22803.33% -90.63%
NET CHANGE
Cash From Operating Activities -25.22M -20.53M -23.94M
Cash From Investing Activities 20.69M -95.02M 11.44M
Cash From Financing Activities 119.0K 137.4M 140.0K
Net Change In Cash -4.406M 21.87M -12.36M
YoY Change -64.36% -127.93% -18.15%
FREE CASH FLOW
Cash From Operating Activities -$25.22M -$20.53M -$23.94M
Capital Expenditures $65.00K -$10.00K $1.488M
Free Cash Flow -$25.28M -$20.52M -$25.43M
YoY Change -0.57% 24.21% 63.63%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6411000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3186000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
24440000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
31775000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
32221000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-27694000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-28336000
CY2020Q1 us-gaap Interest Income Other
InterestIncomeOther
1039000
CY2019Q1 us-gaap Interest Income Other
InterestIncomeOther
1277000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1039000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1277000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26655000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27059000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26655000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27052000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
108000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26540000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26944000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.76
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.05
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35079756
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25668798
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27052000
CY2020Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
115000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8729000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9517000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q1 us-gaap Assets Current
AssetsCurrent
256752000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1780000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
282780000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11975000
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 asmb Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4826000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1830000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1684000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3374000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1731000
CY2019Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
29000000
CY2019Q4 us-gaap Goodwill
Goodwill
12638000
CY2019Q4 us-gaap Assets
Assets
339907000
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5363000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
227311000
CY2020Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3055000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42326000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46732000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
206803000
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4568000
CY2020Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
6715000
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
32000
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8539000
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-466076000
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
21146000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8286000
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32624725
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32624725
CY2020Q1 us-gaap Liabilities
Liabilities
61542000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
29326000
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
717898000
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-86000
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
313310000
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3264000
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4430000
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2104000
CY2020Q1 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
29000000
CY2020Q1 asmb Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
4633000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11479000
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1661000
CY2020Q1 us-gaap Goodwill
Goodwill
12638000
CY2020Q1 us-gaap Assets
Assets
313310000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26655000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
108000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6556000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27052000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
190401000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
2531000
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
30637000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9082000
CY2019Q4 us-gaap Liabilities
Liabilities
66690000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32558307
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32558307
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
32000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
712807000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-201000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-439421000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
251768000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
273217000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
339907000
CY2019Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4924000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6577000
CY2020Q1 asmb Accretion And Amortization Of Investments In Marketable Securities
AccretionAndAmortizationOfInvestmentsInMarketableSecurities
135000
CY2019Q1 asmb Accretion And Amortization Of Investments In Marketable Securities
AccretionAndAmortizationOfInvestmentsInMarketableSecurities
592000
CY2020Q1 asmb Noncash Rent Expense
NoncashRentExpense
1151000
CY2019Q1 asmb Noncash Rent Expense
NoncashRentExpense
1091000
CY2020Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-7000
CY2020Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0
CY2019Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-102000
CY2020Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0
CY2019Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1000
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-319000
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
557000
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-795000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2558000
CY2020Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-23000
CY2019Q1 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-1687000
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
373000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1266000
CY2020Q1 asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
-193000
CY2019Q1 asmb Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
3077000
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3808000
CY2019Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2679000
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1007000
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-859000
CY2020Q1 asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1120000
CY2019Q1 asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1037000
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25218000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23939000
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1488000
CY2020Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
44242000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
49030000
CY2020Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
55000000
CY2019Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
61453000
CY2020Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
10000000
CY2019Q1 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
500000
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20693000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11435000
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
119000
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
140000
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
119000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
140000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4406000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12364000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
46732000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41471000
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
42326000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29107000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
362000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13933000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
273217000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
119000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
115000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4972000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26655000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
251768000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
210653000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
140000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
-4000
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q1 asmb Number Of Approved Products
NumberOfApprovedProducts
0
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include revenue recognition, clinical trial accruals, recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, amounts receivable and recognized as revenue under the Collaboration Agreement, measurement of operating lease liabilities, and the fair value of stock options, stock appreciation rights, and restricted stock units (RSUs) granted to employees, directors and consultants.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</p>
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3030000
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1315000
CY2020Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2020Q1 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2019Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3069000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-26655000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-27052000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35079756000
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25668798000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.76
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.05
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.76
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.05
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7418558
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5756974
CY2020Q1 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
245591000
CY2020Q1 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
387000
CY2020Q1 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
165000
CY2020Q1 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
245813000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
269817000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
79000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
7000
CY2019Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
269889000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1200000
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1780000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1830000
CY2020Q1 us-gaap Depreciation
Depreciation
100000
CY2019Q1 us-gaap Depreciation
Depreciation
100000
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2144000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5312000
CY2020Q1 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
1627000
CY2019Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
2094000
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
659000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
880000
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4430000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8286000
CY2019Q4 asmb Accrued Restructuring Charges Current
AccruedRestructuringChargesCurrent
2100000
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2017Q4 asmb Initial Public Offering Value Of Shares Authorized
InitialPublicOfferingValueOfSharesAuthorized
250000000.0
CY2020Q1 asmb Common Stock Remaining Shares Available For Sale
CommonStockRemainingSharesAvailableForSale
21400000
CY2020Q1 asmb Warrants Exercisable Description
WarrantsExercisableDescription
Per their terms, the outstanding pre-funded warrants to purchase shares of the Company’s common stock generally may not be exercised if the holder’s ownership of the Company’s common stock would exceed 19.99% following such exercise.
CY2019Q4 asmb Proceeds From Sale Of Pre Funded Warrants
ProceedsFromSaleOfPreFundedWarrants
37500000
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2439538
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2439538
CY2020Q1 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2019Q1 asmb Number Of Warrants Exercised
NumberOfWarrantsExercised
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1900000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
3000000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.74
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.71
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4924000
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6577000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34500000
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3100000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3400000
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
37048000
CY2020Q1 asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
CY2020Q1 asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
1007000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
36041000
CY2018Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
40660000
CY2019Q1 asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
CY2019Q1 asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
859000
CY2019Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
39801000
CY2020Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1007000
CY2019Q1 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
859000
CY2020Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2019Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2020Q1 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11800000
CY2020Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11500000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1151000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1091000
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
100000
CY2019Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
321000
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
284000
CY2019Q1 us-gaap Variable Lease Cost
VariableLeaseCost
299000
CY2020Q1 us-gaap Lease Cost
LeaseCost
1535000
CY2019Q1 us-gaap Lease Cost
LeaseCost
1711000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1120000
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1037000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
362000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
13933000
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y4M24D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.094
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3510000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3924000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3560000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3303000
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
14297000
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2494000
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11803000

Files In Submission

Name View Source Status
0001564590-20-023566-index-headers.html Edgar Link pending
0001564590-20-023566-index.html Edgar Link pending
0001564590-20-023566.txt Edgar Link pending
0001564590-20-023566-xbrl.zip Edgar Link pending
asmb-10q_20200331.htm Edgar Link pending
asmb-10q_20200331_htm.xml Edgar Link completed
asmb-20200331.xsd Edgar Link pending
asmb-20200331_cal.xml Edgar Link unprocessable
asmb-20200331_def.xml Edgar Link unprocessable
asmb-20200331_lab.xml Edgar Link unprocessable
asmb-20200331_pre.xml Edgar Link unprocessable
asmb-ex102_85.htm Edgar Link pending
asmb-ex103_84.htm Edgar Link pending
asmb-ex104_83.htm Edgar Link pending
asmb-ex105_82.htm Edgar Link pending
asmb-ex106_465.htm Edgar Link pending
asmb-ex107_81.htm Edgar Link pending
asmb-ex311_12.htm Edgar Link pending
asmb-ex312_11.htm Edgar Link pending
asmb-ex321_14.htm Edgar Link pending
asmb-ex322_10.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending